

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 May 2018 (03.05.2018)



(10) International Publication Number
WO 2018/080917 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 25/28 (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2017/057566

(22) International Filing Date:

20 October 2017 (20.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/412,868 26 October 2016 (26.10.2016) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventor; and

(71) Applicant (for US only): AMERIKS, Michael K.
[US/US]; 3210 Merryfield Row, San Diego, California
92121 (US).

(72) Inventors: AMERIKS, Michael K.; 3210 Merryfield
Row, San Diego, California 92121 (US). GYURIS, Márió;
Magyarország Kft, Berliu u. 47-49, H-1045 Budapest
(HU). LAFORTEZA, Brian Ngo; 3210 Merryfield Row,
San Diego, California 92121 (US). LEBOLD, Terry
Patrick; 3210 Merryfield Row, San Diego, California
92121 (US). MEYER, Stephen Todd; 9885 Mesa Rim
Road, Suite 101, San Diego, California 92121 (US).
RAVULA, Suchitra; 3210 Merryfield Row, San Diego,
California 92121 (US). SAVALL, Brad M.; 9512 Ron-
da Avenue, San Diego, California 92123 (US). SHIRE-
MAN, Brock T.; 3210 Merryfield Row, San Diego, Cali-
fornia 92121 (US). WADE, Warren Stanfield; 9885 Mesa
Rim Road, Suite 101, San Diego, California 92121 (US).
GERENCSE, János; Magyarország Kft, Berliu u. 47-49,
H-1045 Budapest (HU).

(74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON &
JOHNSON, One Johnson & Johnson Plaza, New
Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: FUSED BICYCLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS



(57) Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, (I) Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

WO 2018/080917 A1